Integra LifeSciences Holdings - Asset Resilience Ratio
Integra LifeSciences Holdings (IART) has an Asset Resilience Ratio of 0.98% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Integra LifeSciences Holdings debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2024)
This chart shows how Integra LifeSciences Holdings's Asset Resilience Ratio has changed over time. See IART net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Integra LifeSciences Holdings's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Integra LifeSciences Holdings.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $35.69 Million | 0.98% |
| Total Liquid Assets | $35.69 Million | 0.98% |
Asset Resilience Insights
- Limited Liquidity: Integra LifeSciences Holdings maintains only 0.98% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Integra LifeSciences Holdings Industry Peers by Asset Resilience Ratio
Compare Integra LifeSciences Holdings's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
INKON Life Technology Co Ltd
SHE:300143 |
Medical Devices | 3.37% |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607 |
Medical Devices | 16.21% |
|
Senseonics Holdings, Inc. Common Stock
NYSE MKT:SENS |
Medical Devices | 54.67% |
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO |
Medical Devices | 30.97% |
|
HansBiomed Corporation
KQ:042520 |
Medical Devices | 9.13% |
|
Aligned Genetics Inc
KQ:238120 |
Medical Devices | 2.22% |
|
Heramed Ltd
AU:HMD |
Medical Devices | 0.83% |
|
Acarix A/S
ST:ACARIX |
Medical Devices | 37.81% |
Annual Asset Resilience Ratio for Integra LifeSciences Holdings (1999–2024)
The table below shows the annual Asset Resilience Ratio data for Integra LifeSciences Holdings.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.67% | $27.19 Million | $4.04 Billion | -0.19pp |
| 2023-12-31 | 0.86% | $32.69 Million | $3.78 Billion | +0.44pp |
| 2022-12-31 | 0.43% | $16.68 Million | $3.89 Billion | +0.43pp |
| 2019-12-31 | 0.00% | $12.00K | $3.30 Billion | -0.15pp |
| 2018-12-31 | 0.15% | $4.65 Million | $3.11 Billion | +0.10pp |
| 2017-12-31 | 0.05% | $1.52 Million | $3.21 Billion | +0.03pp |
| 2016-12-31 | 0.01% | $242.00K | $1.81 Billion | -0.22pp |
| 2015-12-31 | 0.23% | $4.07 Million | $1.77 Billion | -- |
| 2014-12-31 | 0.00% | $0.00 | $1.58 Billion | -- |
| 2013-12-31 | 0.00% | $0.00 | $1.20 Billion | -- |
| 2012-12-31 | 0.00% | $0.00 | $1.16 Billion | -- |
| 2011-12-31 | 0.00% | $0.00 | $1.14 Billion | -- |
| 2010-12-31 | 0.00% | $0.00 | $1.02 Billion | -- |
| 2005-12-31 | 17.91% | $80.33 Million | $448.43 Million | +11.14pp |
| 2004-12-31 | 6.78% | $30.95 Million | $456.71 Million | -0.39pp |
| 2003-12-31 | 7.17% | $29.57 Million | $412.53 Million | -12.96pp |
| 2002-12-31 | 20.13% | $55.28 Million | $274.67 Million | +10.38pp |
| 2001-12-31 | 9.75% | $22.18 Million | $227.59 Million | +8.53pp |
| 2000-12-31 | 1.22% | $1.05 Million | $86.51 Million | -5.27pp |
| 1999-12-31 | 6.49% | $4.30 Million | $66.30 Million | -- |
About Integra LifeSciences Holdings
Integra LifeSciences Holdings Corporation manufactures and sells surgical instrument, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural r… Read more